|
Gene: DDX39B |
Gene summary for DDX39B |
Gene summary. |
Gene information | Species | Human | Gene symbol | DDX39B | Gene ID | 7919 |
Gene name | DExD-box helicase 39B | |
Gene Alias | BAT1 | |
Cytomap | 6p21.33 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | A0A024RCM3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7919 | DDX39B | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.05e-23 | 4.15e-01 | 0.0155 |
7919 | DDX39B | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.82e-20 | 5.88e-01 | -0.1808 |
7919 | DDX39B | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.84e-10 | 5.85e-01 | 0.0216 |
7919 | DDX39B | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.76e-31 | 7.71e-01 | -0.0811 |
7919 | DDX39B | HTA11_78_2000001011 | Human | Colorectum | AD | 3.57e-32 | 6.94e-01 | -0.1088 |
7919 | DDX39B | HTA11_347_2000001011 | Human | Colorectum | AD | 3.89e-58 | 9.40e-01 | -0.1954 |
7919 | DDX39B | HTA11_411_2000001011 | Human | Colorectum | SER | 6.89e-14 | 9.53e-01 | -0.2602 |
7919 | DDX39B | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.90e-09 | 5.59e-01 | -0.2196 |
7919 | DDX39B | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.96e-16 | 5.89e-01 | -0.1207 |
7919 | DDX39B | HTA11_83_2000001011 | Human | Colorectum | SER | 2.91e-27 | 7.43e-01 | -0.1526 |
7919 | DDX39B | HTA11_696_2000001011 | Human | Colorectum | AD | 1.66e-48 | 7.71e-01 | -0.1464 |
7919 | DDX39B | HTA11_866_2000001011 | Human | Colorectum | AD | 1.68e-40 | 7.09e-01 | -0.1001 |
7919 | DDX39B | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.17e-42 | 1.01e+00 | -0.059 |
7919 | DDX39B | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.50e-12 | 5.66e-01 | -0.1706 |
7919 | DDX39B | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.91e-11 | 4.78e-01 | -0.2061 |
7919 | DDX39B | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.17e-09 | 4.66e-01 | -0.1462 |
7919 | DDX39B | HTA11_546_2000001011 | Human | Colorectum | AD | 2.07e-24 | 8.00e-01 | -0.0842 |
7919 | DDX39B | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.27e-11 | 4.04e-01 | -0.0179 |
7919 | DDX39B | HTA11_866_3004761011 | Human | Colorectum | AD | 1.47e-27 | 6.15e-01 | 0.096 |
7919 | DDX39B | HTA11_4255_2000001011 | Human | Colorectum | SER | 6.82e-15 | 6.95e-01 | 0.0446 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00902576 | Stomach | CAG with IM | regulation of muscle system process | 25/1050 | 252/18723 | 4.12e-03 | 3.54e-02 | 25 |
GO:00003776 | Stomach | CAG with IM | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 30/1050 | 320/18723 | 4.15e-03 | 3.56e-02 | 30 |
GO:00003986 | Stomach | CAG with IM | mRNA splicing, via spliceosome | 30/1050 | 320/18723 | 4.15e-03 | 3.56e-02 | 30 |
GO:00003756 | Stomach | CAG with IM | RNA splicing, via transesterification reactions | 30/1050 | 324/18723 | 4.95e-03 | 4.01e-02 | 30 |
GO:00718974 | Stomach | CAG with IM | DNA biosynthetic process | 19/1050 | 180/18723 | 6.02e-03 | 4.63e-02 | 19 |
GO:00069136 | Stomach | CAG with IM | nucleocytoplasmic transport | 28/1050 | 301/18723 | 6.09e-03 | 4.68e-02 | 28 |
GO:00511696 | Stomach | CAG with IM | nuclear transport | 28/1050 | 301/18723 | 6.09e-03 | 4.68e-02 | 28 |
GO:004440321 | Stomach | CSG | biological process involved in symbiotic interaction | 36/1034 | 290/18723 | 4.68e-06 | 1.86e-04 | 36 |
GO:004572721 | Stomach | CSG | positive regulation of translation | 22/1034 | 136/18723 | 5.27e-06 | 2.03e-04 | 22 |
GO:007182621 | Stomach | CSG | ribonucleoprotein complex subunit organization | 30/1034 | 227/18723 | 8.31e-06 | 2.97e-04 | 30 |
GO:002261321 | Stomach | CSG | ribonucleoprotein complex biogenesis | 49/1034 | 463/18723 | 9.79e-06 | 3.36e-04 | 49 |
GO:002261821 | Stomach | CSG | ribonucleoprotein complex assembly | 29/1034 | 220/18723 | 1.23e-05 | 4.17e-04 | 29 |
GO:003425021 | Stomach | CSG | positive regulation of cellular amide metabolic process | 23/1034 | 162/18723 | 2.92e-05 | 8.26e-04 | 23 |
GO:005170121 | Stomach | CSG | biological process involved in interaction with host | 26/1034 | 203/18723 | 5.59e-05 | 1.42e-03 | 26 |
GO:004873221 | Stomach | CSG | gland development | 43/1034 | 436/18723 | 1.70e-04 | 3.33e-03 | 43 |
GO:000188921 | Stomach | CSG | liver development | 19/1034 | 147/18723 | 4.78e-04 | 7.42e-03 | 19 |
GO:006100821 | Stomach | CSG | hepaticobiliary system development | 19/1034 | 150/18723 | 6.16e-04 | 8.96e-03 | 19 |
GO:200027821 | Stomach | CSG | regulation of DNA biosynthetic process | 15/1034 | 106/18723 | 7.08e-04 | 9.89e-03 | 15 |
GO:000641721 | Stomach | CSG | regulation of translation | 43/1034 | 468/18723 | 7.58e-04 | 1.04e-02 | 43 |
GO:005116821 | Stomach | CSG | nuclear export | 19/1034 | 154/18723 | 8.52e-04 | 1.15e-02 | 19 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa03015 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa030151 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
hsa030404 | Colorectum | MSI-H | Spliceosome | 37/797 | 217/8465 | 2.49e-04 | 3.23e-03 | 2.70e-03 | 37 |
hsa030405 | Colorectum | MSI-H | Spliceosome | 37/797 | 217/8465 | 2.49e-04 | 3.23e-03 | 2.70e-03 | 37 |
hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa030159 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa030137 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0301514 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa0301312 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304010 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
hsa030155 | Prostate | BPH | mRNA surveillance pathway | 32/1718 | 97/8465 | 2.20e-03 | 8.63e-03 | 5.34e-03 | 32 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDX39B | SNV | Missense_Mutation | novel | c.1126G>T | p.Ala376Ser | p.A376S | Q13838 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDX39B | SNV | Missense_Mutation | c.1013N>A | p.Arg338Gln | p.R338Q | Q13838 | protein_coding | tolerated(0.09) | benign(0.011) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
DDX39B | SNV | Missense_Mutation | novel | c.599N>C | p.Lys200Thr | p.K200T | Q13838 | protein_coding | deleterious(0.03) | possibly_damaging(0.885) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DDX39B | deletion | Frame_Shift_Del | c.447delT | p.Phe149LeufsTer13 | p.F149Lfs*13 | Q13838 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
DDX39B | deletion | Frame_Shift_Del | c.447delN | p.Phe149LeufsTer13 | p.F149Lfs*13 | Q13838 | protein_coding | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
DDX39B | deletion | Frame_Shift_Del | c.447delT | p.Phe149LeufsTer13 | p.F149Lfs*13 | Q13838 | protein_coding | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
DDX39B | deletion | Frame_Shift_Del | c.447delN | p.Phe149LeufsTer13 | p.F149Lfs*13 | Q13838 | protein_coding | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |||
DDX39B | deletion | Frame_Shift_Del | c.447delT | p.Phe149LeufsTer13 | p.F149Lfs*13 | Q13838 | protein_coding | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
DDX39B | deletion | In_Frame_Del | novel | c.814_816delNNN | p.Asn272del | p.N272del | Q13838 | protein_coding | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
DDX39B | SNV | Missense_Mutation | novel | c.1139N>A | p.Arg380Gln | p.R380Q | Q13838 | protein_coding | deleterious(0.01) | possibly_damaging(0.55) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |